Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Neuroscience Bulletin
Erschienen in:

01.04.2019 | Perspective

Brains for Dementia Research: The Importance of Cohorts in Brain Banking

verfasst von: Paul T. Francis, Gillian M. Hayes, Helen Costello, David R. Whitfield

Erschienen in: Neuroscience Bulletin | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Auszug

The collection of brain and related tissue has a long history [1]. In terms of dementia, a more systematic examination of the relationship between brain pathology and clinical symptoms can be traced to Alois Alzheimer’s group in Munich in the early 1900s [2]. The use of human brain tissue is essential to increase our understanding of dementia as it gives us the gold standard of disease pathogenesis and clues as to the molecular mechanisms that underpin the various diseases and conditions. From such human studies, experimental models can be interrogated against this standard and new treatment strategies can be discovered for these socially and economically devastating conditions. …
Literatur
1.
Overy C, Tansey EM (EDs). The Development of Brain Banks in the UK c.1970–c.2010. Welcome Witnesses to Contemporary Medicine 2015, 53: 2018.
2.
Bick KL, Pepeu G (EDs). The Early Story of Alzheimer’s Disease. Padova, Italy: Liviana Press, 1987.
3.
Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976, 99: 459–496.CrossRefPubMed
4.
Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, et al. Neurochemical studies of early-onset Alzheimer’s disease. Possible influence on treatment. N Engl J Med 1985, 313: 7–11.
5.
Clarke NA, Francis PT. Cholinergic and glutamatergic drugs in Alzheimer’s disease therapy. Expert Rev Neurother 2005, 5: 671–682.CrossRefPubMed
6.
Glenner GG, Wong CW. Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984, 120: 885–890.CrossRefPubMed
7.
Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule associated protein tau. Proc Natl Acad Sci U S A 1988, 85: 4051–4055.CrossRefPubMedPubMedCentral
8.
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004, 55: 306–319.CrossRefPubMed
9.
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372: 216–223.CrossRefPubMed
10.
Yan XX, Ma C, Bao AM, Wang XM, Gai WP. Brain banking as a cornerstone of neuroscience in China. Lancet Neurol 2015, 14: 136.CrossRefPubMed
11.
Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, et al. The cost of Alzheimer’s disease in China and re-estimation of costs worldwide. Alzheimers Dement 2018, 14: 483–491.CrossRefPubMed
12.
The Lancet Neurology. Brain banking: more effective strategies needed. Lancet Neurol 2013, 12: 1035.CrossRefPubMed
13.
Ince PG, Minett T, Forster G, Brayne C, Wharton SB, Medical Research Council Cognitive Function and Ageing Neuropathology Study. Microinfarcts in an older population-representative brain donor cohort (MRC CFAS): Prevalence, relation to dementia and mobility, and implications for the evaluation of cerebral Small Vessel Disease. Neuropathol Appl Neurobiol 2017, 43: 409–418.CrossRefPubMed
14.
Samarasekera N, Al-Shahi Salman R, Huitinga I, Klioueva N, McLean CA, Kretzschmar H, et al. Brain banking for neurological disorders. Lancet Neurol 2013, 12: 1096–1105.CrossRefPubMed
15.
Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N, Braak H, et al. Staging of neurofibrillary pathology in Alzheimer’s disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008, 18: 484–496.PubMedPubMedCentral
16.
Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 2012, 123: 1–11.CrossRefPubMed
17.
McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017, 89: 88–100.CrossRefPubMedPubMedCentral
18.
Skrobot OA, Attems J, Esiri M, Hortobagyi T, Ironside JW, Kalaria RN, et al. Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. Brain 2016, 139: 2957–2969.CrossRefPubMed
19.
20.
Rogers SL, Friedhoff LT. The efficacy and safety of donezepil in patients with Alzheimer’s disease: results of a US multicentre randomized, double-blind, placebo-controlled trial. Dementia 1996, 7: 293–303.PubMed
21.
Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999, 66: 137–147.CrossRefPubMedPubMedCentral
22.
Francis PT, Ramirez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer’s disease. Neuropharmacology 2010, 59: 221–229.CrossRefPubMed
23.
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30: 572–580.CrossRefPubMed
24.
25.
Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011, 32: 1207–1218.CrossRefPubMed
26.
Vallortigara J, Whitfield D, Quelch W, Alghamdi A, Howlett D, Hortobagyi T, et al. Decreased levels of VAMP2 and monomeric alpha-synuclein correlate with duration of dementia. J Alzheimers Dis 2016, 50: 101–110.CrossRefPubMed
27.
Baek JH, Whitfield D, Howlett D, Francis P, Bereczki E, Ballard C, et al. Unfolded protein response is activated in Lewy body dementias. Neuropathol Appl Neurobiol 2016, 42: 352–365.CrossRefPubMed
28.
Whitfield DR, Vallortigara J, Alghamdi A, Hortobgyi T, Ballard C, Thomas AJ, et al. Depression and synaptic zinc regulation in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia. Am J Geriatr Psychiatry 2015, 23: 141–148.CrossRefPubMed
29.
Alghamdi A, Vallortigara J, Howlett DR, Broadstock M, Hortobagyi T, Ballard C, et al. Reduction of RPT6/S8 (a Proteasome Component) and proteasome activity in the cortex is associated with cognitive impairment in Lewy body dementia. J Alzheimers Dis 2017, 57: 373–386.CrossRefPubMedPubMedCentral
30.
Bereczki E, Francis PT, Howlett D, Pereira JB, Hoglund K, Bogstedt A, et al. Synaptic proteins predict cognitive decline in Alzheimer’s disease and Lewy body dementia. Alzheimers Dement 2016, 12: 1149–1158.CrossRefPubMed
31.
Bereczki E, Branca RM, Francis PT, Pereira JB, Baek JH, Hortobagyi T, et al. Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. Brain 2018, 141: 582–595.CrossRefPubMedPubMedCentral
32.
Datta A, Chai YL, Tan JM, Lee JH, Francis PT, Chen CP, et al. An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias. Mol Brain 2017, 10: 36.CrossRefPubMedPubMedCentral
33.
Xing H, Lim YA, Chong JR, Lee JH, Aarsland D, Ballard CG, et al. Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with beta-amyloid burden and synaptic deficits in Lewy body dementias. Mol Brain 2016, 9: 84.CrossRefPubMedPubMedCentral
34.
Ferrero H, Larrayoz IM, Martisova E, Solas M, Howlett DR, Francis PT, et al. Increased levels of brain adrenomedullin in the neuropathology of Alzheimer’s disease. Mol Neurobiol 2018, 55: 5177–5183.CrossRefPubMed
35.
Kirvell SL, Esiri MM, Francis PT. Down regulation of vesicular glutamate transporters precede cell loss and pathology in Alzheimer’s disease. J Neurochem 2006, 98: 939–950.CrossRefPubMed
36.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory - comprehensive assessment of psychopathology in dementia. Neurology 1994, 44: 2308–2314.CrossRefPubMed
37.
Whitfield DR, Vallortigara J, Alghamdi A, Howlett D, Hortobagyi T, Johnson M, et al. Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer’s disease: association with cognitive impairment. Neurobiol Aging 2014, 35: 2836–2844.CrossRefPubMed
38.
Vallortigara J, Rangarajan S, Whitfield D, Alghamdi A, Howlett D, Hortobagyi T, et al. Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. F1000Res 2014, 3: 108.CrossRef
39.
Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, et al. Imaging synaptic density in the living human brain. Sci Transl Med 2016, 8: 348ra396.CrossRef
40.
Colom-Cadena M, Pegueroles J, Herrmann AG, Henstridge CM, Munoz L, Querol-Vilaseca M, et al. Synaptic phosphorylated alpha-synuclein in dementia with Lewy bodies. Brain 2017, 140: 3204–3214.CrossRefPubMedPubMedCentral
41.
Hannon E, Lunnon K, Schalkwyk L, Mill J. Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes. Epigenetics 2015, 10: 1024–1032.CrossRefPubMedPubMedCentral
42.
Dammer EB, Duong DM, Diner I, Gearing M, Feng Y, Lah JJ, et al. Neuron enriched nuclear proteome isolated from human brain. J Proteome Res 2013, 12: 3193–3206.CrossRefPubMedPubMedCentral
Metadaten
Titel
Brains for Dementia Research: The Importance of Cohorts in Brain Banking
verfasst von
Paul T. Francis
Gillian M. Hayes
Helen Costello
David R. Whitfield
Publikationsdatum
01.04.2019
Verlag
Springer Singapore
Erschienen in
Neuroscience Bulletin / Ausgabe 2/2019
Print ISSN: 1673-7067
Elektronische ISSN: 1995-8218
DOI
https://doi.org/10.1007/s12264-018-0327-2

Weitere Artikel der Ausgabe 2/2019

Progress in Human Brain Banking in China

  • EDITORIAL

Pathological Changes to the Subcortical Visual System and its Relationship to Visual Hallucinations in Dementia with Lewy Bodies

  • Perspective

The rs2228570 Variant of the Vitamin D Receptor Gene is Associated with Essential Tremor

  • Letter to the Editor

Kir2.1 Channel Regulation of Glycinergic Transmission Selectively Contributes to Dynamic Mechanical Allodynia in a Mouse Model of Spared Nerve Injury

  • Original Article

Altered Local Field Potential Relationship Between the Parafascicular Thalamic Nucleus and Dorsal Striatum in Hemiparkinsonian Rats

  • Open Access
  • Original Article

Brain Banking for Research into Neurodegenerative Disorders and Ageing

  • Perspective

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Ehe schützt nicht vor Demenz

  • 25.04.2025
  • Demenz
  • Nachrichten

Eigentlich leben Verheiratete länger und gesünder. Eine aktuelle Untersuchung kommt jedoch zu dem überraschenden Schluss, dass sie eher an Demenz erkranken als nie Verheiratete, Geschiedene oder Verwitwete.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Neuartige Antikörpertherapie bremst MS über zwei Jahre hinweg

Eine Therapie mit dem C40-Ligand-Blocker Frexalimab kann MS-Schübe und neue MRT-Läsionen über zwei Jahre hinweg verhindern. Dafür spricht die Auswertung einer offen fortgeführten Phase-2-Studie.

Therapiestopp bei älteren MS-Kranken kann sich lohnen

Eine Analyse aus Kanada bestätigt: Setzen ältere MS-Kranke die Behandlung mit Basistherapeutika ab, müssen sie kaum mit neuen Schüben und MRT-Auffälligkeiten rechnen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise